Methotrexate as effective as prednisone in pulmonary sarcoidosis
Study indicates it could be an alternative first-line treatment to the steroid, which causes unwanted side effects
2025-05-18
(Press-News.org) EMBARGOED UNTIL: 9:15 a.m. PT/12:15 p.m. ET, Sunday, May 18, 2025
Session: A14—Advances in the Diagnosis and Management of ILD
Methotrexate Versus Prednisone as First-line Treatment for Pulmonary Sarcoidosis: The Predmeth Trial
Date and Time: Sunday, May 18, 2025, 9:15 a.m.
Location: Room 25, Hall E (North Building, Exhibition Level), Moscone Center
ATS 2025, San Francisco – Prednisone is recommended as the first-line treatment for pulmonary sarcoidosis, but this steroid causes a number of unwanted side effects. Now new research published at the ATS 2025 International Conference finds that methotrexate provides a comparable alternative.
Researchers found that methotrexate was as effective in controlling the disease, with potentially fewer side effects than prednisone. The randomized, controlled trial, conducted as part of a collaboration among 17 hospitals in the Netherlands, provides the first high-quality data comparing the two therapies in patients with pulmonary sarcoidosis.
“The results of this trial show that methotrexate can be offered as an alternative for prednisone for patients with pulmonary sarcoidosis,” said first author Vivienne Kahlmann, MD, a pulmonologist in training at Erasmus Medical Center in Rotterdam, Netherlands.
Sarcoidosis is a complex immunological disease with a highly variable clinical course and prognosis. While some patients experience spontaneous remission, others require immunosuppressive treatment to maintain organ function and improve quality of life.
Even though international guidelines recommend prednisone to be used as standard-of-care for pulmonary sarcoidosis, these recommendations have not been based on randomized clinical trials. Prednisone is often accompanied by side effects like weight gain, sleep disturbance, and psychological symptoms, which can negatively affect patients’ quality of life. In addition, long-term use is associated with a high risk of chronic complications.
For the PREDMETH trial, researchers compared 69 patients who received prednisone for pulmonary sarcoidosis with 68 who received methotrexate. They found that methotrexate was non-inferior to prednisone after 24 weeks of treatment but had a slower onset of efficacy.
Although the total number of side effects were similar, the methotrexate group had fewer ongoing side effects at 24 weeks. The side effects themselves were also different, with weight gain, insomnia, and increased appetite most common in the prednisone group, and nausea, fatigue, and liver function abnormalities common in the methotrexate group.
“Results were in line with what we hypothesized,” last-author Marlies Wijsenbeek, MD, a pulmonologist at the Erasmus Medical Center said. “It was, however, surprising to see that some symptom scores already improved after four weeks of treatment in the methotrexate group. She said the findings will help doctors and patients make more personalized treatment plans, noting that treatment decisions should be based on individual patients’ preferences and needs.
“Some patients prioritize fast improvement of symptoms and are less afraid of side effects, while other patients may want to wait longer for treatment effects if this means they can avoid steroid toxicity,” Dr. Kahlmann noted.
Looking ahead, researchers plan to develop a decision-aid tool to help doctors and patients navigate treatment choices. They also plan follow-up studies, including analyzing blood samples from study participants to identify cellular biomarkers to predict treatment response.
###
VIEW ABSTRACT
You may also be interested in these abstracts.
CONTACT FOR MEDIA:
Dacia Morris
dmorris@thoracic.org
David Drexhage
d.drexhage@erasmusmc.nl
Contact details first and last author:
Vivienne Kahlmann
v.kahlmann@erasmusmc.nl
Marlies Wijsenbeek
m.wijsenbeek-lourens@erasmusmc.nl
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-05-18
Belgrade, Serbia – 18 May 2025. Waist-to-height ratio predicts heart failure incidence, according to research presented today at Heart Failure 2025,1 a scientific congress of the European Society of Cardiology (ESC).
Obesity affects a substantial proportion of patients with heart failure (HF) and it has been reported that the risk of HF increases as body mass index (BMI) increases.2 Study presenter, Dr. Amra Jujic from Lund University, Malmö, Sweden, explained why the current analysis was carried out: “BMI is the most common measure ...
2025-05-18
Session: A109—Smoke, Snooze, and ICU Blues: The Influence of Environmental Exposures and Critical Care Conditions on Sleep
Rising Temperatures Are Associated with Increased Burden of Obstructive Sleep Apnea
Date and Time: Sunday, May 18, 2025, 2:15 p.m.
Location: Room 2022/2024 (West Building, Level 2), Moscone Center
ATS 2025, San Francisco – Rising temperatures increase the severity of obstructive sleep apnea (OSA), according to a large new study published at the ATS 2025 International Conference. The study also found that, under the most likely climate ...
2025-05-18
LOS ANGELES — Surgeons from Keck Medicine of USC and UCLA Health have performed the world’s first-in-human bladder transplant. The surgery was successfully completed at Ronald Reagan UCLA Medical Center on May 4, 2025, in a joint effort by Inderbir Gill, MD, founding executive director of USC Urology, and Nima Nassiri, MD, urologic transplant surgeon and director of the UCLA Vascularized Composite Bladder Allograft Transplant Program.
Groundbreaking moment in medical history
“This surgery is a historic ...
2025-05-18
If you have cancer, you expect to see an oncologist, but if you have heart failure you may or may not see a cardiologist. According to research published in the European Heart Journal [1] today (Sunday), only around three out of five heart failure patients see a cardiologist at least once a year.
The study, also presented at Heart Failure Congress 2025, shows that patients who do see a cardiologist once a year are around 24% less likely to die in the following year. It also shows which patients could benefit from seeing a cardiologist once a year and which patients should be seen more often.
The ...
2025-05-17
Belgrade, Serbia – 17 May 2025. An artificial intelligence-enabled electrocardiogram-based algorithm performed well in the early detection of heart failure among healthcare-seeking individuals in Kenya, according to late-breaking research presented today at Heart Failure 2025,1 a scientific congress of the European Society of Cardiology (ESC).
Heart failure is highly prevalent in Sub-Saharan Africa, where patients are often younger and face worse outcomes than in high-income countries.2 Explaining the rationale for ...
2025-05-17
Belgrade, Serbia – 17 May 2025. A pharmaceutically produced cannabidiol formulation had a good overall safety profile, including cardiac safety, according to research presented today at Heart Failure 2025,1 a scientific congress of the European Society of Cardiology (ESC).
Currently, there are limited treatment options for inflammatory conditions of the heart, such as myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the membrane surrounding the heart). Cannabidiol – which lacks the psychotropic effects of cannabis – has been shown to inhibit activation of the inflammasome pathway,2 an intracellular ...
2025-05-17
Tokyo, Japan – Researchers from Tokyo Metropolitan University have solved a long-standing mystery behind the drainage of liquid from foams. Standard physics models wildly overestimate the height of foams required for liquid to drain out the bottom. Through careful observation, the team found that the limits are set by the pressure required to rearrange bubbles, not simply push liquid through a static set of obstacles. Their approach highlights the importance of dynamics to understanding soft materials.
When you spray a foam on a wall, ...
2025-05-17
Materials with self-adaptive mechanical responses have long been sought after in material science. Using computer simulations, researchers at the Tata Institute of Fundamental Research (TIFR), Hyderabad, now show how such adaptive behavior can emerge in active glasses, which are widely used as models for biological tissues. The findings provide new insights—ranging from how cells might regulate their glassiness to aiding in the design of new metamaterials.
Glasses (or amorphous solids) are materials whose components ...
2025-05-17
Laser Ion acceleration uses intense laser flashes to heat electrons of a solid to enormous temperatures and propel these charged particles to extreme speeds. These have recently gained traction for applications in selectively destroying cancerous tumor cells, in processing semiconductor materials, and due to their excellent properties - for imaging and fusion relevant conditions.
Massive laser systems with several Joules of light energy are needed to irradiate solids for the purpose. This produces a flash of ions which are accelerated to extreme speeds. Thus, emulating large million volt accelerators is possible ...
2025-05-16
University of Cambridge media release
Life, death and mowing – study reveals Britain’s poetic obsession with the humble lawnmower
UNDER STRICT EMBARGO UNTIL 00:01AM (UK TIME) ON SATURDAY 17TH MAY 2025
Over the last half-century, British poets including Philip Larkin and Andrew Motion have driven a ‘lawnmower poetry microgenre’, using the machine to explore childhood, masculinity, violence, addiction, mortality and much more, new research shows.
The study, published today in Critical Quarterly, argues that the tradition goes back to the 17th-century poet Andrew Marvell who used mowing – with a scythe – to comment ...
LAST 30 PRESS RELEASES:
[Press-News.org] Methotrexate as effective as prednisone in pulmonary sarcoidosis
Study indicates it could be an alternative first-line treatment to the steroid, which causes unwanted side effects
